RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 11.76

Change

+0.15 (+1.26)%

Market Cap

N/A

Volume

2.60K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-15 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

+0.12 (+0.26%)

USD 1.27B
PSQ ProShares Short QQQ

-0.05 (-0.12%)

USD 0.61B
SPXU ProShares UltraPro Short S&P50..

+0.19 (+0.74%)

USD 0.55B
SOXS Direxion Daily Semiconductor B..

-0.34 (-1.45%)

USD 0.46B
YANG Direxion Daily FTSE China Bear..

+0.78 (+1.77%)

USD 0.27B
SDOW ProShares UltraPro Short Dow30

+0.71 (+1.31%)

USD 0.25B
SPDN Direxion Daily S&P 500® Bear ..

+0.02 (+0.17%)

USD 0.21B
RWM ProShares Short Russell2000

-0.02 (-0.09%)

USD 0.18B
FNGD MicroSectors FANG+ Index -3X I..

-0.34 (-2.26%)

USD 0.18B
DOG ProShares Short Dow30

+0.11 (+0.40%)

USD 0.13B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.18% 33% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.18% 33% F 67% D+
Trailing 12 Months  
Capital Gain 1.47% 86% B+ 54% F
Dividend Return 2.52% 62% D 44% F
Total Return 3.99% 84% B 50% F
Trailing 5 Years  
Capital Gain -59.92% 80% B- 6% D-
Dividend Return 2.98% 77% C+ 6% D-
Total Return -56.94% 80% B- 6% D-
Average Annual (5 Year Horizon)  
Capital Gain 66.18% 39% F 96% N/A
Dividend Return 67.61% 39% F 96% N/A
Total Return 1.43% 62% D 34% F
Risk Return Profile  
Volatility (Standard Deviation) 433.11% 63% D 3% F
Risk Adjusted Return 15.61% 54% F 32% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.